WEST PHARMACEUTICAL SERVICES INC (WST) earnings date, results and what the price requires
NYSE · SEC CIK 0000105770 · SEC filings checked Oct 16, 2026
Previous results (SEC filings)
| Quarter ended | Reported | Revenue | Net income | Diluted EPS | Source |
|---|---|---|---|---|---|
| Jun 30, 2026 | Jul 23, 2026 | $872.3M | $154.0M | $2.15 | Filing |
| Mar 31, 2026 | Apr 23, 2026 | $844.9M | $138.8M | $1.92 | Filing |
| Dec 31, 2025 | Feb 12, 2026 | $805.0M | $132.1M | $1.82 | Filing |
| Sep 30, 2025 | Oct 23, 2025 | $804.6M | $140.0M | $1.92 | Filing |
| Jun 30, 2025 | Jul 24, 2025 | $766.5M | $131.8M | $1.82 | Filing |
| Mar 31, 2025 | Apr 24, 2025 | $698.0M | $89.8M | $1.23 | Filing |
| Dec 31, 2024 | Feb 13, 2025 | $748.8M | $130.1M | $1.78 | Filing |
| Sep 30, 2024 | Oct 24, 2024 | $746.9M | $136.0M | $1.85 | Filing |
What would WEST PHARMACEUTICAL SERVICES INC have to report for its valuation to change?
At $383.02, with a 9.0% required return and a 18× earnings multiple in 5 years, earnings per share must grow about 33.2% a year, to $32.74. On that path the next quarter needs diluted EPS near $2.56, against $1.92 in the quarter ended Sep 30, 2025.
Compare buying at the last close now with waiting for results: if the report moves the growth the price requires, the entry price you would accept changes with it.
| Result | Original | Yours |
|---|---|---|
| Required EPS growth / year | 33.2% | 33.2% |
| EPS needed in final year | $32.74 | $32.74 |
Changed: nothing yet. Model: EPS × (1+g)^years × final P/E, discounted at the required return, equals today's price. Inputs: SEC diluted EPS and the dated close above.
Prepare for earnings across my investments — $399/month
Keep working models for the companies you follow, compare your expectations with reported results, and review what changes your investment decision. WST goes in with your buy-or-wait comparison and assumptions preserved.
Figures come from SEC EDGAR XBRL filings. Dates marked "estimated" are calculated from the company's past results filings and are not confirmed. Not investment advice.